GlassScriptPhysician profile
Andrew J Milano
NPI 1144418047
$1,274.18
in general payments reported to CMS, 2019-2025
18 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.10 · 2022: $178 · 2023: $307 · 2024: $379 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $313.01 | 2022-2025 | Ozempic |
| Abbvie INC. | $148.24 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.38 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $107.69 | 2022-2025 | |
| Glaxosmithkline, LLC. | $98.86 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $74.45 | 2023-2025 | |
| Exact Sciences Corporation | $58.77 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $48.50 | 2022 | |
| Abbott Laboratories | $45.72 | 2023 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $43.66 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.37 | 2023-2024 | Jardiance |
| Amgen INC. | $31.78 | 2022-2025 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $23.45 | 2022 | |
| Fidia Pharma USA INC. | $23.10 | 2022 | |
| Vertos Medical, INC. | $20.55 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Milano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.